Key result
Chlormadinone acetate therapy for 1 week significantly reduced arterial CO2 tension by 4.6 +/- 0.6 mmHg and increased occlusion pressure response to CO2 compared to placebo (p<0.01).
Why the study?
Does chlormadinone acetate improve ventilatory control and pulmonary gas exchange in patients with COPD?
RCT (n=12)
Double-blind
randomized cross-over
Does chlormadinone acetate improve ventilatory control and pulmonary gas exchange in patients with COPD?
Mean Difference: -4.6
Chlormadinone acetate significantly reduces arterial CO2 tension and augments respiratory neuromuscular response to hypercapnia and hypoxia in patients with COPD.
May aid hypercapnia management in COPD; leaves open durability, safety, and outcome impact.
Twelve patients with chronic obstructive pulmonary disease (COPD) were studied to determine the effect of ventilatory stimulation with chlormadinone acetate (CMA), a potent synthetic progesterone, on chemical and neuromechanical respiratory controls and pulmonary gas exchange. Using a randomized, double-blind, cross-over trial, 1 wk of CMA therapy caused a significant reduction in arterial CO2 tension (Paco2) by 4.6 +/- 0.6 (SE) mmHg. This Paco2 fall was associated with increased minute ventilation (Vl), tidal volume (VT), and mean inspiratory flow (VT/Tl). During CMA administration, occlusion pressure response to CO2 with and without inspiratory flow-resistive loading increased significantly (p less than 0.01) over that during placebo administration, whereas ventilatory response to CO2 did not. In addition, normocapnic ventilatory and occlusion pressure response to hypoxia were significantly elevated (p less than 0.01) during CMA therapy. Furthermore, the degree of load compensation, which was assessed by the ratio of the loaded to unloaded slope in the occlusion pressure response to CO2, increased in all subjects after CMA administration. These results indicate that CMA augments not only the respiratory neuromuscular response to hypercapnia and hypoxia, but also flow-resistive load compensation in patients with COPD, and it may provide support for the use of CMA in patients who are able to decrease their Paco2 with this agent.
No takes yet. Share an insight, caveat, or question.
Tatsumi et al. (1986) conducted an RCT in chronic obstructive pulmonary disease (COPD) (n=12). chlormadinone acetate vs. placebo was evaluated on arterial CO2 tension (Paco2) (reduction of 4.6 +/- 0.6 (SE) mmHg). Chlormadinone acetate therapy for 1 week significantly reduced arterial CO2 tension by 4.6 +/- 0.6 mmHg and increased occlusion pressure response to CO2 compared to placebo (p<0.01).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: